Corline Biomedical (CLBIO) Q3 2024 earnings summary

Executive summary

• Implemented a new strategy focused on supporting Kardium's US launch, expanding medtech business, and partnering for Renaparin® to drive revenue and reach profitability by end of 2025.

• Q3 2024 saw a temporary revenue dip but significant cost reductions, positioning for future growth as new product launches approach.

• Strategic focus includes three pillars: supporting Kardium, expanding medtech customer base, and early-stage Renaparin® partnerships.

Financial highlights

• Q3 2024 net revenue: 1,770 KSEK (5,310 KSEK Q3 2023); 9M 2024 net revenue: 7,763 KSEK (18,786 KSEK 9M 2023).

• Q3 2024 net income: -2,996 KSEK (179 KSEK Q3 2023); 9M 2024 net income: -9,033 KSEK (-1,209 KSEK 9M 2023).

• Q3 2024 EPS: -0.14 SEK (0.01 SEK Q3 2023); 9M 2024 EPS: -0.42 SEK (-0.06 SEK 9M 2023).

• Cash and cash equivalents at period end: 7,334 KSEK (17,000 KSEK prior year).

• Q3 2024 operating expenses reduced to 5,737 KSEK (7,970 KSEK Q3 2023), reflecting cost control and lower clinical project costs.

Outlook and guidance

• Expectation of revenue growth as CHS™-coated products launch in the US and new customer projects mature.

• Profitability targeted by end of 2025, supported by cost reductions and strategic focus.

• Available liquidity and planned 18 MSEK directed share issue expected to fund operations until positive cash flow.